FDA clears Medtronic's Hugo surgical robot for general surgery
The clearance covers upper and lower abdominal procedures, which Medtronic says add up to about 3.5 million US surgeries a year.

Medtronic announced this week that the FDA has cleared its Hugo robotic surgery system for general surgery. The clearance spans upper abdominal operations, among them gallbladder removal, gastric bypass, ventral hernia repair and small bowel resection, plus two lower abdominal ones: inguinal hernia repair and appendectomy. Medtronic says these account for about 3.5 million US surgeries a year. Hugo was already cleared for urology in December 2025.
Medtronic won CE marking for general surgery in Europe in 2022 and used that data alongside a US clinical trial run under an investigational device exemption. Rajit Kamal, general manager of robotic surgical technologies, says general surgery is Hugo's fastest-growing procedural mix outside the US, and the system is on track for 50,000 cumulative procedures by the end of the fiscal year. Medtronic is also running a gynecology study, invested $700 million in Cornerstone Robotics in September and wants to bring AI features to Hugo.
Why it matters
Kamal says access depends on cost, training and support, and that Medtronic is open to financial arrangements with hospitals. No pricing was given. Watch for US hospital adoption, the gynecology study results and the first AI features on Hugo.